Cancer Research Cell Death Mechanisms and Cancer Therapy Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Medina, D.
Right arrow Articles by Lydon, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Medina, D.
Right arrow Articles by Lydon, J.
[Cancer Research 63, 1067-1072, March 1, 2003]
© 2003 American Association for Cancer Research

Tumor Biology

Hormone Dependence in Premalignant Mammary Progression1

Daniel Medina2, Frances S. Kittrell, Anne Shepard, Alejandro Contreras, Jeffrey M. Rosen and John Lydon

Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030

Human breast cancers that are estrogen receptor (ER) negative convey a poor prognosis for patient survival. A mouse model that mimics essential biological and genetic attributes of a subset of human breast cancer is the BALB/c p53-null mammary epithelium, in which deletion of the tumor suppressor gene p53 results in enhanced tumorigenic risk. The experiments reported herein examine the hormone dependence of premalignant mammary progression in this model. The p53-null normal mammary epithelium exhibits the same dependence as p53 wild-type mammary epithelium on ovarian hormones for growth. However, in contrast to p53 wild-type epithelium, estrogen and progesterone, singly or in combination, strongly enhance tumorigenesis in p53-null mammary epithelium. The removal of progesterone signaling by deletion of the progesterone receptor eliminates progesterone enhancement of tumorigenesis. The immortalized premalignant outgrowth lines, termed PN, possess different tumorigenic capabilities, but the majority of these lines showed a strong dependence on ovarian hormones for growth and tumorigenesis. Although these lines are highly ER positive, a large number of tumors arising from these lines were ER negative and grew when implanted in ovariectomized mice. As was the case for p53-null normal mammary cells, hormonal stimulation was a strong promoter for tumorigenesis in the premalignant outgrowth lines and, surprisingly, was much stronger than the chemical carcinogen 7,12-dimethylbenzanthracene. In summary, these results demonstrate that p53-null mammary cells, which generate a significant percentage of ER-negative tumors, are highly responsive to the absence or presence of ovarian hormones during the normal and premalignant stages. This model would appear an excellent one to test the effects of chemopreventive agents on the development of both ER-negative and ER-positive mammary tumors.




This article has been cited by other articles:


Home page
 J EndocrinolHome page
L. M Arendt, L. C Evans, D. E Rugowski, M. J. Garcia-Barchino, H. Rui, and L. A Schuler
Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes
J. Endocrinol., October 1, 2009; 203(1): 99 - 110.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. P. Lydon and D. P. Edwards
Finally! A Model for Progesterone Receptor Action in Normal Human Breast
Endocrinology, July 1, 2009; 150(7): 2988 - 2990.
[Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
T. A. Rose-Hellekant, A. J. Skildum, O. Zhdankin, A. L. Greene, R. R. Regal, K. D. Kundel, and D. W. Kundel
Short-term Prophylactic Tamoxifen Reduces the Incidence of Antiestrogen-Resistant/Estrogen Receptor-Positive/Progesterone Receptor-Negative Mammary Tumors
Cancer Prevention Research, May 1, 2009; 2(5): 496 - 502.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
L. M. Arendt, T. L. Grafwallner-Huseth, and L. A. Schuler
Prolactin-Growth Factor Crosstalk Reduces Mammary Estrogen Responsiveness Despite Elevated ER{alpha} Expression
Am. J. Pathol., March 1, 2009; 174(3): 1065 - 1074.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. R. Loehberg, T. Thompson, M. B. Kastan, K. H. Maclean, D. G. Edwards, F. S. Kittrell, D. Medina, O. M. Conneely, and B. W. O'Malley
Ataxia Telangiectasia-Mutated and p53 Are Potential Mediators of Chloroquine-Induced Resistance to Mammary Carcinogenesis
Cancer Res., December 15, 2007; 67(24): 12026 - 12033.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S M Hyder
Sex-steroid regulation of vascular endothelial growth factor in breast cancer.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 667 - 687.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Zhang, L. C. Stephens, and R. Kumar
Metastasis Tumor Antigen Family Proteins during Breast Cancer Progression and Metastasis in a Reliable Mouse Model for Human Breast Cancer
Clin. Cancer Res., March 1, 2006; 12(5): 1479 - 1486.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
Y. Tu, D. J. Jerry, B. Pazik, and S. Smith Schneider
Sensitivity to DNA Damage Is a Common Component of Hormone-Based Strategies for Protection of the Mammary Gland
Mol. Cancer Res., August 1, 2005; 3(8): 435 - 442.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Medina, F. S. Kittrell, J. Hill, A. Shepard, G. Thordarson, and P. Brown
Tamoxifen Inhibition of Estrogen Receptor-{alpha}-Negative Mouse Mammary Tumorigenesis
Cancer Res., April 15, 2005; 65(8): 3493 - 3496.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
I. U. Agoulnik, X.-W. Tong, D.-C. Fischer, K. Korner, N. E. Atkinson, D. P. Edwards, D. R. Headon, N. L. Weigel, and D. G. Kieback
A Germline Variation in the Progesterone Receptor Gene Increases Transcriptional Activity and May Modify Ovarian Cancer Risk
J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6340 - 6347.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Hu, H. Sun, J. Drake, F. Kittrell, M. C. Abba, L. Deng, S. Gaddis, A. Sahin, K. Baggerly, D. Medina, et al.
From Mice to Humans: Identification of Commonly Deregulated Genes in Mammary Cancer via Comparative SAGE Studies
Cancer Res., November 1, 2004; 64(21): 7748 - 7755.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Pati, B. R. Haddad, A. Haegele, H. Thompson, F. S. Kittrell, A. Shepard, C. Montagna, N. Zhang, G. Ge, S. K. Otta, et al.
Hormone-Induced Chromosomal Instability in p53-Null Mammary Epithelium
Cancer Res., August 15, 2004; 64(16): 5608 - 5616.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Gattelli, M. C. Cirio, A. Quaglino, C. Schere-Levy, N. Martinez, M. Binaghi, R. P. Meiss, L. H. Castilla, and E. C. Kordon
Progression of Pregnancy-Dependent Mouse Mammary Tumors after Long Dormancy Periods. Involvement of Wnt Pathway Activation
Cancer Res., August 1, 2004; 64(15): 5193 - 5199.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. E. Maglione, E. T. McGoldrick, L. J.T. Young, R. Namba, J. P. Gregg, L. Liu, D. Moghanaki, L. G. Ellies, A. D. Borowsky, R. D. Cardiff, et al.
Polyomavirus middle T-induced mammary intraepithelial neoplasia outgrowths: Single origin, divergent evolution, and multiple outcomes
Mol. Cancer Ther., August 1, 2004; 3(8): 941 - 953.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Medina and F. S. Kittrell
p53 Function Is Required for Hormone-Mediated Protection of Mouse Mammary Tumorigenesis
Cancer Res., October 1, 2003; 63(19): 6140 - 6143.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.